Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arbutus Biopharma CorpABUS · Entity 4953 | Director | June 03, 2021 | June 07, 2021 |
| Damora Therapeutics, Inc.DMRA · Entity 4602 | Director | August 12, 2026 | August 13, 2026 |
| TCGX Acquisition Corp.TCGX · Entity 6504 | Director | August 04, 2026 | August 04, 2026 |
| Vera Therapeutics, Inc.VERA · Entity 4358 | Director | May 21, 2026 | May 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arbutus Biopharma Corp
Report date June 03, 2021 · Filed June 07, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.95 · Expires 2031-06-03 | Direct | 22,000 |
Reported balance
After 2021-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-03 · Grant · Acquired 22,000 · Balance 22,000 F1: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on June 3, 2021, the date of the grant. F2: The options are fully vested and exercisable as of the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on June 3, 2021, the date of the grant.
F2: The options are fully vested and exercisable as of the date of the grant.
Damora Therapeutics, Inc.
Report date August 12, 2026 · Filed August 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.00 · Expires 2036-08-12 | Direct | 30,350 |
Reported balance
After 2026-08-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-12 · Grant · Acquired 30,350 · Balance 30,350 F1: This option represents a right to purchase shares of common stock of the Issuer. This option will vest in equal monthly installments through August 12, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase shares of common stock of the Issuer. This option will vest in equal monthly installments through August 12, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
TCGX Acquisition Corp.
Report date August 04, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-08-04 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares immediately prior to, concurrently with or immediately following the consummation of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person, on a one-for-one basis, subject to adjustment, and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares immediately prior to, concurrently with or immediately following the consummation of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person, on a one-for-one basis, subject to adjustment, and have no expiration date.
Vera Therapeutics, Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.35 · Expires 2036-05-20 | Direct | 17,084 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 17,084 · Balance 17,084 F1: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Akero Therapeutics, Inc.
Report date December 09, 2025 · Filed December 09, 2025
Section 16 reporting ended · disclosed 2025-12-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2025-12-09 · Disposition to issuer · Disposed 277,075 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 9, 2025 (such date and time, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. At the Effective Time, each share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was cancelled and converted into the right to receive (i) cash in an amount equal to $54.00 (the "Closing Consideration") and (ii) one contractual contingent value right (a "CVR") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement) ((i) and (ii), together, the "Merger Consideration"). |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2025-12-09 · Disposition to issuer · Disposed 159,762 · Balance 0 F2: Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the Company RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive the Merger Consideration in respect of each such Company RSU. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.23 · Expires 2034-12-16 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-12-09 · Disposition to issuer · Disposed 3,421 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.87 · Expires 2033-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-12-09 · Disposition to issuer · Disposed 5,032 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.95 · Expires 2032-12-09 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-12-09 · Disposition to issuer · Disposed 2,328 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.10 · Expires 2031-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-12-09 · Disposition to issuer · Disposed 4,739 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.35 · Expires 2030-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-12-09 · Disposition to issuer · Disposed 3,527 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.23 · Expires 2034-12-16 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-12-09 · Disposition to issuer · Disposed 292,179 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.87 · Expires 2033-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-12-09 · Disposition to issuer · Disposed 374,985 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.95 · Expires 2032-12-09 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-12-09 · Disposition to issuer · Disposed 233,252 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.10 · Expires 2031-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2025-12-09 · Disposition to issuer · Disposed 23,809 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.10 · Expires 2031-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2025-12-09 · Disposition to issuer · Disposed 165,289 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.10 · Expires 2031-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2025-12-09 · Disposition to issuer · Disposed 87,220 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.35 · Expires 2030-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2025-12-09 · Disposition to issuer · Disposed 238,973 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.09 · Expires 2029-12-13 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2025-12-09 · Disposition to issuer · Disposed 234,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2029-06-19 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2025-12-09 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 9, 2025 (such date and time, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. At the Effective Time, each share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was cancelled and converted into the right to receive (i) cash in an amount equal to $54.00 (the "Closing Consideration") and (ii) one contractual contingent value right (a "CVR") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement) ((i) and (ii), together, the "Merger Consideration").
F2: Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the Company RSU.
F3: Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive the Merger Consideration in respect of each such Company RSU.
F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 10, 2025 Filed Feb 11, 2025 21:30 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 200 | $55.81 | $11,162.00 |
DisclosureSEC source: 0000950170-25-018311 · ownership.xml · nonDerivative · entry 5 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 686,062 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person. Read SEC document |
| February 10, 2025 Filed Feb 11, 2025 21:30 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 749 | $54.55 | $40,854.95 |
DisclosureSEC source: 0000950170-25-018311 · ownership.xml · nonDerivative · entry 4 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 686,262 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $54.355 to $54.930, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 10, 2025 Filed Feb 11, 2025 21:30 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 9,972 | $53.67 | $535,157.35 |
DisclosureSEC source: 0000950170-25-018311 · ownership.xml · nonDerivative · entry 3 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 687,011 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $53.355 to $54.345, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 10, 2025 Filed Feb 11, 2025 21:30 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 6,439 | $52.91 | $340,674.61 |
DisclosureSEC source: 0000950170-25-018311 · ownership.xml · nonDerivative · entry 2 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 696,983 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $52.350 to $53.345, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 10, 2025 Filed Feb 11, 2025 21:30 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 12,640 | $51.75 | $654,145.28 |
DisclosureSEC source: 0000950170-25-018311 · ownership.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 703,422 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $51.340 to $52.330, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 20:43 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 3,377 | $56.89 | $192,117.53 |
DisclosureSEC source: 0000950170-25-010705 · ownership.xml · nonDerivative · entry 3 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 716,062 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $56.430 to $57.010, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 20:43 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 2,381 | $55.53 | $132,216.93 |
DisclosureSEC source: 0000950170-25-010705 · ownership.xml · nonDerivative · entry 2 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 719,439 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $55.255 to $56.010, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 20:43 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 24,242 | $54.56 | $1,322,643.52 |
DisclosureSEC source: 0000950170-25-010705 · ownership.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 721,820 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 16, 2024, previously adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $54.190 to $55.165, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 18:07 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0000950170-25-009324 · ownership.xml · derivative · entry 2 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,212 Underlying: Common Stock · 50,000 shares Expires 2028-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options are vested and currently exercisable. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 18:07 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 50,000 | $0.62 | $30,750.00 |
DisclosureSEC source: 0000950170-25-009324 · ownership.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 746,062 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 20:50 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GrantStock Option (Right to Buy) · Derivative | 295,600 | $0.00 Strike: $29.23 | $0.00 |
DisclosureSEC source: 0000950170-24-138132 · ownership.xml · derivative · entry 2 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 295,600 Underlying: Common Stock · 295,600 shares Expires 2034-12-15 F2 · derivative.exercise_date: This option shall vest and become exercisable in forty-eight (48) equal monthly installments, commencing from December 16, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 20:50 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GrantCommon Stock | 98,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-138132 · ownership.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 696,062 F1 · shares: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in eight (8) equal semi-annual installments, commencing from December 16, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| December 10, 2024 Filed Dec 12, 2024 20:24 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 7,855 | $30.79 | $241,855.45 |
DisclosureSEC source: 0000950170-24-136017 · ownership.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 597,562 F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $30.79 to $30.93, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 19:36 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $21.10 | $0.00 |
DisclosureSEC source: 0000950170-24-133435 · ownership.xml · derivative · entry 3 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,029 Underlying: Common Stock · 0 shares Expires 2031-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 25, 2023, previously adopted by the Reporting Person. F3 · derivative.exercise_date: The options are vested and currently exercisable. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 19:36 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 25,000 | $32.09 | $802,250.00 |
DisclosureSEC source: 0000950170-24-133435 · ownership.xml · nonDerivative · entry 2 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 605,417 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 25, 2023, previously adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.59 to $32.54, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 19:36 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 25,000 | $21.10 | $527,500.00 |
DisclosureSEC source: 0000950170-24-133435 · ownership.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 630,417 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 25, 2023, previously adopted by the Reporting Person. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 09:00 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 27,086 | $0.00 Strike: $21.10 | $0.00 |
DisclosureSEC source: 0000950170-24-121100 · ownership.xml · derivative · entry 6 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,029 Underlying: Common Stock · 0 shares Expires 2031-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 25, 2023, previously adopted by the Reporting Person. F4 · derivative.exercise_date: The options are vested and currently exercisable. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 09:00 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 81,280 | $0.00 Strike: $21.10 | $0.00 |
DisclosureSEC source: 0000950170-24-121100 · ownership.xml · derivative · entry 5 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 163,115 Underlying: Common Stock · 0 shares Expires 2031-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 25, 2023, previously adopted by the Reporting Person. F4 · derivative.exercise_date: The options are vested and currently exercisable. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 09:00 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 27,086 | $32.50 | $880,267.91 |
DisclosureSEC source: 0000950170-24-121100 · ownership.xml · nonDerivative · entry 4 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 605,417 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 25, 2023, previously adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.10 to $32.94, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 09:00 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 27,086 | $21.10 | $571,514.60 |
DisclosureSEC source: 0000950170-24-121100 · ownership.xml · nonDerivative · entry 3 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 632,503 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 25, 2023, previously adopted by the Reporting Person. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 09:00 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 81,280 | $31.47 | $2,558,044.16 |
DisclosureSEC source: 0000950170-24-121100 · ownership.xml · nonDerivative · entry 2 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 605,417 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 25, 2023, previously adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.10 to $32.09, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 09:00 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 81,280 | $21.10 | $1,715,008.00 |
DisclosureSEC source: 0000950170-24-121100 · ownership.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 686,697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 25, 2023, previously adopted by the Reporting Person. Read SEC document |
| October 18, 2024 Filed Oct 18, 2024 20:57 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Righto Buy) · Derivative | 63,539 | $0.00 Strike: $21.10 | $0.00 |
DisclosureSEC source: 0000950170-24-115731 · ownership.xml · derivative · entry 10 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,709 Underlying: Common Stock · 185,343 shares Expires 2031-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 25, 2023, previously adopted by the Reporting Person. F5 · derivative.exercise_date: The options are vested and currently exercisable. Read SEC document |
| October 18, 2024 Filed Oct 18, 2024 20:57 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 226 | $32.12 | $7,259.12 |
DisclosureSEC source: 0000950170-24-115731 · ownership.xml · nonDerivative · entry 7 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 605,417 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 25, 2023, previously adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.12 to $32.13, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document |
| October 18, 2024 Filed Oct 18, 2024 20:57 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 63,313 | $31.53 | $1,996,068.95 |
DisclosureSEC source: 0000950170-24-115731 · ownership.xml · nonDerivative · entry 6 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 605,643 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 25, 2023, previously adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.10 to $32.07, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document |
| October 18, 2024 Filed Oct 18, 2024 20:57 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 63,539 | $21.10 | $1,340,672.90 |
DisclosureSEC source: 0000950170-24-115731 · ownership.xml · nonDerivative · entry 5 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 668,956 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 25, 2023, previously adopted by the Reporting Person. Read SEC document |
| October 17, 2024 Filed Oct 18, 2024 20:57 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Righto Buy) · Derivative | 3,103 | $0.00 Strike: $21.10 | $0.00 |
DisclosureSEC source: 0000950170-24-115731 · ownership.xml · derivative · entry 9 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,248 Underlying: Common Stock · 185,343 shares Expires 2031-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 25, 2023, previously adopted by the Reporting Person. F5 · derivative.exercise_date: The options are vested and currently exercisable. Read SEC document |
| October 17, 2024 Filed Oct 18, 2024 20:57 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 3,103 | $31.12 | $96,559.15 |
DisclosureSEC source: 0000950170-24-115731 · ownership.xml · nonDerivative · entry 4 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 605,417 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 25, 2023, previously adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.10 to $31.22, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document |
| October 17, 2024 Filed Oct 18, 2024 20:57 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 3,103 | $21.10 | $65,473.30 |
DisclosureSEC source: 0000950170-24-115731 · ownership.xml · nonDerivative · entry 3 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 608,520 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 25, 2023, previously adopted by the Reporting Person. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 20:57 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Righto Buy) · Derivative | 24,992 | $0.00 Strike: $21.10 | $0.00 |
DisclosureSEC source: 0000950170-24-115731 · ownership.xml · derivative · entry 8 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 160,351 Underlying: Common Stock · 185,343 shares Expires 2031-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 25, 2023, previously adopted by the Reporting Person. F5 · derivative.exercise_date: The options are vested and currently exercisable. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 20:57 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 24,992 | $31.14 | $778,150.91 |
DisclosureSEC source: 0000950170-24-115731 · ownership.xml · nonDerivative · entry 2 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 605,417 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 25, 2023, previously adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.10 to $31.22, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 20:57 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 24,992 | $21.10 | $527,331.20 |
DisclosureSEC source: 0000950170-24-115731 · ownership.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 630,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 25, 2023, previously adopted by the Reporting Person. Read SEC document |
| September 10, 2024 Filed Sep 13, 2024 17:10 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 1,738 | $26.18 | $45,500.84 |
DisclosureSEC source: 0000950170-24-106451 · ownership.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 605,417 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 11:45 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 24,538 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0000950170-24-098933 · ownership.xml · derivative · entry 2 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,538 shares Expires 2028-10-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options are vested and currently exercisable. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 11:45 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 24,538 | $0.62 | $15,090.87 |
DisclosureSEC source: 0000950170-24-098933 · ownership.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 607,155 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 28, 2024 Filed Jul 2, 2024 18:55 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GrantCommon Stock | 1,064 | $19.94 | $21,217.22 |
DisclosureSEC source: 0000950170-24-080922 · ownership.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 582,617 F1 · shares: Dr. Cheng is voluntarily reporting the acquisition of these shares on June 28, 2024 pursuant to the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(c) and Rule 16b-3(d). F2 · price: In accordance with the provisions of the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan, these shares were purchased at 85% of the closing price of the Issuer's common stock on June 28, 2024. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 18:01 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 7,894 | $22.64 | $178,728.05 |
DisclosureSEC source: 0000950170-24-073181 · ownership.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 581,553 F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.640 to $22.760, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:08 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $42.69 | $0.00 |
DisclosureSEC source: 0001415889-24-013470 · form4-05172024_080535.xml · derivative · entry 1 Cheng Andrew · CIK 0001778307 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,000 Underlying: Class A Common Stock · 14,000 shares Expires 2034-05-14 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2025 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 16:43 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 1,969 | $28.33 | $55,781.77 |
DisclosureSEC source: 0000950170-24-032263 · ownership.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 589,447 F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 20:14 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,267 | $0.00 Strike: $21.10 | $0.00 |
DisclosureSEC source: 0000950170-24-027510 · ownership.xml · derivative · entry 10 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 244,395 Underlying: Common Stock · 17,267 shares Expires 2031-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 24, 2023, previously adopted by the Reporting Person F8 · derivative.exercise_date: The options are vested and currently exercisable. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 20:14 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 57,733 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000950170-24-027510 · ownership.xml · derivative · entry 9 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 57,733 shares Expires 2029-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 24, 2023, previously adopted by the Reporting Person F8 · derivative.exercise_date: The options are vested and currently exercisable. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 20:14 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 114 | $36.28 | $4,135.92 |
DisclosureSEC source: 0000950170-24-027510 · ownership.xml · nonDerivative · entry 8 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 591,416 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 24, 2023, previously adopted by the Reporting Person Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 20:14 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 7,995 | $35.49 | $283,775.33 |
DisclosureSEC source: 0000950170-24-027510 · ownership.xml · nonDerivative · entry 7 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 591,530 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 24, 2023, previously adopted by the Reporting Person F7 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.245 to $36.16, inclusive. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 20:14 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 14,680 | $34.63 | $508,372.80 |
DisclosureSEC source: 0000950170-24-027510 · ownership.xml · nonDerivative · entry 6 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 599,525 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 24, 2023, previously adopted by the Reporting Person F6 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.19 to $35.18, inclusive. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 20:14 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 9,614 | $33.83 | $325,266.62 |
DisclosureSEC source: 0000950170-24-027510 · ownership.xml · nonDerivative · entry 5 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 614,205 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 24, 2023, previously adopted by the Reporting Person F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $33.19 to $34.18, inclusive. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 20:14 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 6,770 | $32.28 | $218,537.63 |
DisclosureSEC source: 0000950170-24-027510 · ownership.xml · nonDerivative · entry 4 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 623,819 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 24, 2023, previously adopted by the Reporting Person F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.12 to $32.85, inclusive. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 20:14 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 35,827 | $31.40 | $1,124,974.97 |
DisclosureSEC source: 0000950170-24-027510 · ownership.xml · nonDerivative · entry 3 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 630,589 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 24, 2023, previously adopted by the Reporting Person F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.11 to $32.09, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (7) to this Form 4. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 20:14 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 17,267 | $21.10 | $364,333.70 |
DisclosureSEC source: 0000950170-24-027510 · ownership.xml · nonDerivative · entry 2 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 666,416 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 24, 2023, previously adopted by the Reporting Person Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 20:14 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 57,733 | $16.00 | $923,728.00 |
DisclosureSEC source: 0000950170-24-027510 · ownership.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 649,149 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 24, 2023, previously adopted by the Reporting Person F2 · balance_after: Includes 505 shares acquired under the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan on June 30, 2023. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 17:00 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0000950170-24-001053 · ownership.xml · derivative · entry 2 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,538 Underlying: Common Stock · 40,000 shares Expires 2028-10-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options are vested and currently exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.